What is the Viterra deal and why does it matter here?

Bunge's $10 billion-plus acquisition of Viterra is cited in the report as an additional risk layered on top of an already-leveraged balance sheet. Spruce Point's broader thesis is that large acquisition-driven companies tend to make increasingly poor deals as they grow — the Viterra transaction is presented as consistent with that pattern.

Why does Spruce Point bring up GLP-1 drugs in a report about an agribusiness company?

The report notes that Bunge sells into the food products industry and has said nothing about the potential demand impact of GLP-1 weight-loss drugs in its SEC filings or conference calls. Spruce Point argues Bunge is likely feeling effects from that consumer trend — though the firm's own framing acknowledges this is a belief rather than a documented finding.

What prior short reports does Spruce Point cite to establish its track record?

The report references prior Spruce Point work on Xylem (XYL), Stryker (SYK), Generac (GNRC), A. O. Smith (AOS), and MGP Ingredients (MGPI). In each case, the firm highlights post-report outcomes including share price declines ranging from -15% to -80%, executive departures, regulatory actions, or admissions of undisclosed issues.

Is there a connection between Bunge and Spruce Point's prior MGP Ingredients short?

Yes. MGP Ingredients formerly disclosed that Bunge Milling, Inc. was one of its two principal grain suppliers. Spruce Point notes that MGPI no longer references Bunge in that context, which it suggests may indicate a strained or ended supply relationship. MGPI stock fell roughly 80% from the levels at which Spruce Point flagged concerns, eventually trading below $20 by 2025–2026.

What does Spruce Point mean by calling Bunge a "roll-up"?

A roll-up is a company that grows primarily through acquisitions rather than organic business expansion. Spruce Point argues that Bunge fits this pattern — building scale through deals while the underlying business has failed to generate cumulative positive cash flow. The firm's broader thesis is that roll-up strategies tend to obscure weakening fundamentals until the deals stop working.

Has Bunge responded to the Spruce Point report?

No response from Bunge to the Spruce Point report is described in the research. Spruce Point did not include any statement or comment from the company in the materials reviewed.

Spruce Point Targets Bunge (BG), Alleging Debt-Fueled Growth, Weak Cash Flow and Accounting Risks, With 55%

Spruce Point's forensic review identifies several converging threats beyond the cash flow concerns: COFCO, a Chinese state-backed agribusiness with a structurally lower cost of capital, is aggressively expanding across South America where Bunge holds more than 25% of its long-lived assets; the $10 billion-plus Viterra acquisition strains an already-leveraged balance sheet; newly added 10-K language acknowledges oilseed competitors for the first time — a segment once described as Bunge's most difficult-to-replicate advantage; and the report flags undisclosed GLP-1 exposure given Bunge's food industry customer base. Spruce Point CIO Ben Axler frames the thesis bluntly: S&P 500 membership is not a substitute for due diligence.

Ticker: BG (Bunge Global SA)
Research Firm: Spruce Point Capital Management
Report URL: https://www.sprucepointcap.com/research/bunge-global-sa?ref=shortreport.fyi
Position Disclosure: Spruce Point discloses that it holds a material short position in Bunge Global SA and may hold short positions or options in other securities referenced in the report. Subscribers and clients may also hold such positions.

Thesis

Spruce Point's forensic financial review argues that Bunge is a complex, acquisition-driven roll-up that has not generated genuine economic cash, relies on debt to fund shareholder returns, and faces mounting competitive pressure in its core businesses — making it materially overvalued.

Debt-Funded Returns: Since 1999, Bunge generated a cash flow deficit of -$1.6 billion after capital expenditures, business investment, and asset-shuffling — yet paid out $4.7 billion in dividends and $3.9 billion in share repurchases, which Spruce Point characterizes as effectively debt-financed.
Investigation Demanded: The report alleges Bunge's financial reporting and accounting are sufficiently concerning to warrant an independent investigation into their accuracy.
Oilseeds Under Siege: Oilseeds was once Bunge's highest EBIT contributor and had been presented as a global-leading, difficult-to-replicate business. The latest 10-K newly added language acknowledging that “certain of our competitors have added oilseed processing and refining capacity in response to growing demand” — a disclosure the report treats as a material competitive admission.
COFCO Threat: Spruce Point alleges COFCO, a Chinese state-backed company with deep access to capital, poses a particular threat through aggressive infrastructure expansion in South America — precisely where Bunge has more than 25% of its long-lived assets.
China and Feed Pressure: Spruce Point alleges Bunge is also feeling pressure in China and its animal feed business due to changing policies and excess capacity.
Undisclosed GLP-1 Exposure: Despite selling into the food products industry, Bunge has said nothing in SEC filings or conference calls about the potential demand impact of GLP-1 weight-loss drugs. Spruce Point's view that this represents meaningful exposure is circumstantial — the company has not confirmed it.
Viterra Deal Risk: The report flags the $10 billion-plus Viterra acquisition as an additional strain on an already-leveraged balance sheet, consistent with Spruce Point's broader pattern-of-bad-deals thesis.

Notable Details

Bunge returned $8.6 billion to shareholders through dividends and buybacks since 1999 — against a backdrop of -$1.6 billion in cumulative cash flow after capital expenditures and business investment.
The new oilseed competition language in Bunge's 10-K was not present in prior filings, according to the report — Spruce Point treats its sudden appearance as a tell rather than routine disclosure.
COFCO is described as effectively state-owned, giving it a structurally different cost of capital than Bunge in competing for South American infrastructure and origination capacity.
In its prior short on MGP Ingredients — where Bunge Milling was named as a principal grain supplier — MGPI's stock fell roughly 80% from the levels at which Spruce Point flagged concerns, eventually trading below $20 by 2025–2026.
Xylem, Stryker, Generac, and A. O. Smith are all cited as prior S&P 500 roll-up shorts where Spruce Point reports preceded significant executive turnover, regulatory action, or share price declines ranging from -15% to -60%.

“Being an S&P 500 index member is a validation of absolutely nothing and enhanced due diligence is necessary since the bigger a company gets, the greater the pressures to grow and the worse deals management generally makes.”

— Spruce Point CIO Ben Axler, framing the report's central argument that Bunge's blue-chip status should not insulate it from scrutiny.

FAQs

What is Spruce Point's core argument against Bunge (BG)?

Spruce Point argues that Bunge is an acquisition-driven roll-up that has failed to generate genuine economic cash, having posted a cumulative cash flow deficit of -$1.6 billion since 1999 after capital expenditures and business investment. The firm also alleges that Bunge's financial reporting and accounting warrant an independent investigation, and that competitive pressure in oilseeds, Latin America, China, and animal feed creates substantial downside risk to the stock.

How much downside does Spruce Point see in Bunge stock?

Spruce Point estimates approximately 55%–80% downside risk in BG shares from current levels. That range is unusually severe for a large-cap S&P 500 company and reflects the firm's view that Bunge's valuation does not account for deteriorating fundamentals or potential reporting issues.

Does Spruce Point have a financial stake in this report?

Yes. Spruce Point discloses a material short position in Bunge Global SA, meaning it stands to profit if the stock falls. The firm also notes that its subscribers and clients may hold short or options positions in BG and other securities mentioned in the report.

What is the cash flow deficit claim about Bunge?

The report's forensic financial review found that since 1999, Bunge generated a cumulative cash flow deficit of -$1.6 billion after accounting for capital expenditures, business investment, and what Spruce Point describes as asset-shuffling and repositioning. Over the same period, Bunge paid out $4.7 billion in dividends and $3.9 billion in share repurchases — returns Spruce Point characterizes as effectively financed through debt rather than internally generated cash.

Why is Bunge's oilseeds business a concern?

Oilseeds was once Bunge's highest EBIT contributor and had been described by the company as a global-leading business that was difficult to replicate. Spruce Point highlights a sentence newly added to Bunge's most recent 10-K — acknowledging that competitors have added oilseed processing and refining capacity — as a sign that Bunge's competitive moat in that segment is eroding.

Who is COFCO and why does Spruce Point flag it as a threat to Bunge?

COFCO (China Oil and Foodstuffs Corp) is a Chinese state-backed agribusiness that Spruce Point identifies as a particular competitive pressure point for Bunge. The report alleges COFCO has deep access to state capital and has made aggressive infrastructure investments across South America — a region where Bunge has more than 25% of its long-lived assets, making it directly exposed to COFCO's expansion.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://www.sprucepointcap.com/research/bunge-global-sa?ref=shortreport.fyi, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.

Spruce Point Targets Bunge (BG), Alleging Debt-Fueled Growth, Weak Cash Flow and Accounting Risks, With 55%–80% Downside Seen